Cerebroside-A provides potent neuroprotection after cerebral ischaemia through reducing glutamate release and Ca²⁺ influx of NMDA receptors

Int J Neuropsychopharmacol. 2012 May;15(4):497-507. doi: 10.1017/S1461145711000654. Epub 2011 May 4.

Abstract

Excessive presynaptic glutamate release after cerebral ischaemia leads to neuronal death mainly through excessive calcium entry of N-methyl-D-aspartate receptors (NMDARs). Our recent study reported that cerebroside can open large-conductance Ca²⁺-activated K⁺ (BKCa) channels. The present study evaluated the effects of cerebroside-A (CS-A), a single molecule isolated from an edible mushroom, on brain injury after focal or global ischaemia in adult male mice and rats. We herein report that treatment with CS-A after 60-min middle cerebral artery occlusion dose-dependently reduced the cerebral infarction with at least a 6-h efficacious time-window, which was partially blocked by the BKCa channel blocker charybdotoxin (CTX). Treatment with CS-A after 20 min global cerebral ischaemia (four-vessel occlusion) significantly attenuated the death of pyramidal cells in hippocampal CA1 area, which was also sensitive to CTX. CS-A, by opening the BKCa channel, could prevent excessive glutamate release after oxygen-glucose deprivation (OGD). In addition, CS-A could inhibit NMDAR Ca²⁺ influx, which did not require the activation of the BKCa channel. Furthermore, CS-A blocked the OGD-induced NMDAR-dependent long-term potentiation in hippocampal CA1 region. These findings indicate that treatment with CS-A after stroke exerts potent neuroprotection through prevention of excessive glutamate release and reduction of Ca²⁺ influx through NMDARs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 6-Cyano-7-nitroquinoxaline-2,3-dione / pharmacology
  • Analysis of Variance
  • Animals
  • Brain Ischemia / prevention & control
  • Calcium / metabolism*
  • Cerebral Infarction / etiology
  • Cerebral Infarction / prevention & control*
  • Cerebrosides / chemistry
  • Cerebrosides / therapeutic use*
  • Charybdotoxin / pharmacology
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Electric Stimulation
  • Excitatory Amino Acid Antagonists / pharmacology
  • Excitatory Postsynaptic Potentials / drug effects
  • Glucose / deficiency
  • Glutamic Acid / metabolism*
  • Hippocampus / drug effects
  • Hippocampus / physiology
  • Hypoxia / prevention & control
  • In Vitro Techniques
  • Infarction, Middle Cerebral Artery / complications
  • Infarction, Middle Cerebral Artery / drug therapy
  • Long-Term Potentiation / drug effects
  • Long-Term Potentiation / physiology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • N-Methylaspartate / pharmacology
  • Neuroprotective Agents / chemistry
  • Neuroprotective Agents / therapeutic use*
  • Neurotoxins / pharmacology
  • Patch-Clamp Techniques
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, N-Methyl-D-Aspartate / physiology*
  • Tetrazolium Salts
  • Valine / analogs & derivatives
  • Valine / pharmacology

Substances

  • Cerebrosides
  • Excitatory Amino Acid Antagonists
  • Neuroprotective Agents
  • Neurotoxins
  • Receptors, N-Methyl-D-Aspartate
  • Tetrazolium Salts
  • cerebroside A
  • Charybdotoxin
  • Glutamic Acid
  • N-Methylaspartate
  • 6-Cyano-7-nitroquinoxaline-2,3-dione
  • 2-amino-5-phosphopentanoic acid
  • triphenyltetrazolium
  • Valine
  • Glucose
  • Calcium